Statins: Beneficial or Adverse for Glucose Metabolism

1) Brown MS and Goldstein JL: How LDL receptors influence cholesterol and atherosclerosis. Sci Am, 1984; 251: 58-66.

10.1016/S0140-6736(94)92521-6

3) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, and Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 1995; 333: 1301-1307.

2000, 7, 110, 10.5551/jat1994.7.110

10.1161/01.CIR.0000139312.10076.BA

10.1097/00041552-200203000-00001

10.1507/endocrj.52.369

8) Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, and Canon CP: High dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. Circulation, 2004; 110 (Suppl I): S834.

9) Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfalane PW, McKillop JH, Packard CJ, Shepherd J, and Gaw A: Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 2001; 103: 357-362.

10.1016/S0140-6736(02)11798-3

10.1016/S0140-6736(03)13636-7

10.1016/S0140-6736(03)12948-0

10.1056/NEJMoa040583

10.1016/S0140-6736(04)16895-5

ITO H, 2001, 8, 33, 10.5551/jat1994.8.33

SHIMAMOTO KAZUAKI, 1999, 19, 2123

10.1016/S0009-8981(01)00589-7

10.5551/jat.11.341

KAMEDA WATARU, 2003, 24, 851

SATO NOBUYUKI, 2001, 21, 1741

HAMANO YUTAKA, 2002, 22, 2730

SASAMO TOKAZUO, 2003, 23, 2381

SUZUKI DAISUKE, 2005, 25, 2170

24)Yamada N, Kawazu S, Utsugi T, Morisaki N, Saito Y, Teramoto T, Ishibashi S, Fujita T, Shib T, Iwamoto Y, Kuzuya N, Yoshino G, and Akanuma Y: Efficacy of pitavastatin for lipid metabolism in non-insulin-dependent diabetes mellitus. Rinsho-Iyaku, 2001; 17: 945-956.

25)Yamada Y: Evaluation of effectiveness of HMG-CoA reductase inhibitor, pitavastatin, in hypercholesterolemic patients with type 2 diabetes mellitus (in Japanese, with title translated by the authors). Pharma Medica, 2005; 23: 115-119.

SEINO HIROAKI, 2003, 23, 727

27)Osaki F, Ikeda S, Suehiro T, Ota K, Ui K, Kunon Y, and Hashimoto K: Effect of statins on glucose metabolism (in Japanese, with title translated by the authors). Jpn J Clin Exp Med, 2005; 82: 359-363.

10.1016/S0002-9149(01)01696-4

29)Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, and Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation, 1994; 89: 2519-2524.

10.1016/S0140-6736(99)01046-6

31)Yudkin JS, Stehouwer CD, Emeis JJ, and Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol, 1999; 19: 972-978.

10.1038/39335

10.1126/science.271.5249.665

10.1016/S0014-5793(01)03007-1

10.5551/jat.12.111

36)Yada T, Nakata M, Shiraishi T, and Kakei M: Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca²⁺ signaling and insulin secretion due to blockade of L-type Ca²⁺ channels in rat islet β-cells. Brit J Pharmacol, 1999; 126: 1205-1213.

37)Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, Matsuura T, Suzuki H, Kurose T, Yamada Y, and Seino Y: Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism, 2004; 53: 831-835.